Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy Jan 25, 2024 07:00AM
Orchard Therapeutics (ORTX) Receives Swissmedic Approval for Libmeldy in Early-onset MLD Dec 11, 2023 07:18AM
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD Dec 11, 2023 07:00AM
Orchard Therapeutics (ORTX) Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH Nov 30, 2023 07:00AM
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH Nov 30, 2023 07:00AM
View Older Stories

Nov 13, 2023 07:00AM Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
Oct 26, 2023 07:00AM Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
Oct 24, 2023 07:00AM Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
Oct 5, 2023 04:44AM Orchard Therapeutics (ORTX) Acquired by Kyowa Kirin for $16/sh Cash plus $1 CVR
Oct 5, 2023 03:35AM Kyowa Kirin to Acquire Orchard Therapeutics
Sep 18, 2023 07:02AM Orchard Therapeutics (ORTX) Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
Sep 18, 2023 07:00AM Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
Aug 31, 2023 07:00AM Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
Aug 3, 2023 07:01AM Orchard Therapeutics Plc (ORTX) Completes Submission of BLA for OTL-200 in MLD to U.S. FDA
Aug 3, 2023 07:00AM Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
Aug 2, 2023 09:11AM Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
Jul 25, 2023 07:00AM Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
Jun 26, 2023 07:08AM Orchard Therapeutics (ORTX) Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
Jun 26, 2023 07:00AM Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
May 24, 2023 07:00AM Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
May 19, 2023 09:01AM Orchard Therapeutics (ORTX) Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
May 19, 2023 09:00AM Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
May 18, 2023 07:00AM Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
May 15, 2023 07:00AM Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. F
May 15, 2023 02:00AM OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
May 3, 2023 07:03AM Orchard Therapeutics Plc (ORTX) Presents New Clinical and Pre-clinical Data
May 3, 2023 07:00AM Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
Mar 30, 2023 07:00AM Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
Mar 30, 2023 07:00AM Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
Mar 10, 2023 10:00AM Orchard Therapeutics Completes ADS Ratio Change
Mar 10, 2023 10:00AM Orchard Therapeutics Completes ADS Ratio Change
Mar 6, 2023 06:06AM Orchard Therapeutics (ORTX) Issues Business Update, Reports FY22 Results
Mar 6, 2023 06:05AM Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
Mar 6, 2023 06:05AM Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
Mar 6, 2023 06:03AM Orchard Therapeutics Plc (ORTX) Enters Up to $188M Strategic Financing
Mar 6, 2023 06:00AM Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
Mar 6, 2023 06:00AM Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
Mar 3, 2023 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
Mar 3, 2023 07:00AM Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
Feb 27, 2023 07:01AM Orchard Therapeutics Plc (ORTX) Enters Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
Feb 27, 2023 07:00AM Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
Feb 27, 2023 07:00AM Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
Feb 24, 2023 07:05AM Orchard Therapeutics Plc (ORTX) Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts
Feb 24, 2023 07:00AM Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
Feb 24, 2023 07:00AM Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
Feb 10, 2023 07:02AM Orchard Therapeutics Plc (ORTX) Announces Proposed ADS Ratio Change
Feb 10, 2023 07:00AM Orchard Therapeutics Announces Proposed ADS Ratio Change
Feb 10, 2023 07:00AM Orchard Therapeutics Announces Proposed ADS Ratio Change
Feb 8, 2023 07:00AM Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
Feb 8, 2023 07:00AM Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium
Jan 9, 2023 07:00AM Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Jan 9, 2023 07:00AM Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones
Jan 5, 2023 07:01AM Orchard Therapeutics (ORTX) Granted FDA Clearance of IND Application for OTL-203 in MPS-IH
Jan 5, 2023 07:00AM Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
Jan 5, 2023 07:00AM Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH
View Older Stories